SpermQT Prospective Observational Trial

Launched by INHERENT BIOSCIENCES · Jul 20, 2023

Keywords

ClinConnect Summary

The SpermQT Prospective Observational Trial is a study designed to evaluate a new test called the Epigenetic Sperm Quality Test (SpermQT). This test aims to help doctors understand the quality of a man's sperm and how it relates to the success of fertility treatments, specifically intrauterine insemination (IUI). If you or your partner are considering IUI or have recently completed the procedure, this trial might be of interest to you.

To participate, men should be under 45 years old and their female partners should be under 38. Additionally, the man's sperm count must be at least 10 million motile sperm per analysis. However, if either partner has a high body mass index (BMI of 40 or more), has taken testosterone therapy recently, or has certain medical conditions affecting fertility, they may not be eligible. If you join the study, you can expect to undergo the SpermQT test, which could provide valuable information about your sperm quality and help guide your fertility journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The subjects have been recommended to pursue IUI, or they have recently completed an IUI (regardless of outcome)
• • Male partner is under 45 years of age
• • Female partner is under 38 years of age
• • The total motile sperm count from the raw semen analysis must be greater than or equal to 10 million
• Exclusion Criteria:
• • The female or male partner have a BMI equal to or greater than 40
• • The male partner has undergone male testosterone replacement therapy in the last 6 months
• • Either the female or male partner have a history of recurrent pregnancy loss, defined as 2 or more consecutive clinical/ultrasound pregnancy losses
• * There are any known factors contributing to female factor infertility, such as but not limited to:
• • Severe Endometriosis (stage 3 or higher, endometrioma on ovaries)
• • Multiple uterine fibroids 5cm or larger
• • Severe Asherman's Syndrome
• • Severe Mullerian anomaly
• • Lack of tubal patency in at least one fallopian tubes